HERC Seminar: Multi-Criteria Decision Analysis for Comparative Value Assessment throughout the Drug Lifecycle
Dr Tommi Tervonen, Research Scientist and Consultant at Evidera, London, UK
Thursday, 13 December 2018, 2.30pm to 3.30pm
First Floor Main Meeting Room, Richard Doll Building, Old Road Campus, OX3 7LF
Multi-Criteria Decision Analysis (MCDA) has been proposed as appropriate methodology for supporting many key decisions in the drug lifecycle, including regulatory authorization, health technology assessment (HTA) and prescription. The relevant decision criteria are different in these three settings: regulatory MCDAs are mostly concerned with assessing treatment benefit-risk profiles, prescription ones additionally consider convenience and patient satisfaction, and HTAs value cost and equity aspects. This presentation will question whether any single methodology can support decisions as diverse as these, but it will also argue for the value of MCDA as a general framework for structuring comparative treatment assessments. I will demonstrate the use of MCDA in benefit-risk assessment, discuss flaws present in most applications of MCDA in HTA, and argue against application of MCDA in prescription setting.
Dr. Tommi Tervonen is a Research Scientist at the Patient Preference Team of Patient-Centered Research group of Evidera, a for-profit consultancy. In his role, he serves as a principal investigator in health preference research projects. Before joining Evidera in 2015 he was an assistant professor at the Erasmus School of Economics in Rotterdam, and has held a post of visiting professor at the Systems Analysis Laboratory of Aalto University, Helsinki. He currently serves as an associate editor of Decision Support Systems. In the past, he has acted as a reviewer for the European Commission’s 2015–2019 policy impact assessment guidelines. Tommi holds a double-degree PhD (with distinction) in computer science from University of Turku (Finland) and in management science from University of Coimbra (Portugal).